Amedisys — Q4 2023 Earnings Presentation
16 slides from Amedisys's earnings presentation, Feb 21, 2024
Slide 1: Amedisys Fourth Quarter 2023 Earnings Release Supplemental Slides
1 Amedisys Fourth Quarter 2023 Earnings Release Supplemental Slides February 21st, 2024 Exhibit 99.2
Slide 2: Forward-Looking Statements
2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could c
Slide 3: Our Key Areas of Focus
3 OUR KEY AREAS OF FOCUS Strategic areas of focus and progress made during Q4’23 • Home Health: Total same store admissions +7% • Hospice: Total same store ADC flat • High Acuity Care: Admissions +46% over prior year 1 Organic Growth • Quality: Amedisys Apr’24 preview STARS score of 4.35 • 96% of ca
Slide 4: Highlights and Summary Financial Results (Adjusted): 4Q 23
4 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 4Q 2023(1) Excluding the sale of our personal care segment, our revenue increased $25 million over prior year. EBITDA is down $3 million; however, our results were impacted by increases in incentive compensation costs and the divestiture of our
Slide 5: Revenue Mix and Reimbursement by Segment
5 61.6%12.0% 26.4% Home Health Revenue Medicare FFS Private Episodic Per Visit 62.9% 36.1% 1.0% Amedisys Consolidated Revenue Home Health Hospice High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us for a 30-day period o
Slide 6: Home Health and Hospice Segment (Adjusted) – Q4 2023
6 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – Q4 2023(1) • Medicare revenue per episode up 0.1%; reimbursement is flat year over year. • Y/Y Total CPV up $4.96 (+4.3%) primarily due to raises, wage inflation, an increase in new hire pay and higher contractor costs. The reduction in VPE on our episo
Slide 7: General & Administrative Expenses – Adjusted
7 $ in Millions 4Q22 1Q23 2Q23 3Q23 4Q23 Home Health Segment - Total 89.9$ 89.0$ 90.1$ 91.3$ 92.7$ % of HH Revenue 26.1% 25.9% 25.8% 26.0% 25.8% Hospice Segment - Total 50.8 47.9 47.9 48.4 48.6 % of HSP Revenue 25.7% 24.8% 24.0% 24.2% 23.6% Personal Care Segment - Total 2.4 2.2 - - - % of PC Revenue
Slide 8: Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted
8 $45.00 $75.00 $105.00 4Q22 3Q23 4Q23 Cost Per Visit (CPV) Salaries Contractors Benefits Transportation OPERATIONAL EXCELLENCE: HOME HEALTH COST PER VISIT (CPV)-ADJUSTED YOY Total CPV impacted by higher labor costs. *Note: Direct comparison with industry competitors CPV calculation ** Note: In 4Q’2
Slide 9: Driving Top Line Growth
9 DRIVING TOP LINE GROWTH 1% 5% 3% 3% 5% 5% 8% 4% 4% 7% -2.0% 0.0% 2.0% 4.0% 6.0% 8.0% 50,000 100,000 150,000 4Q22 1Q23 2Q23 3Q23 4Q23 Volume SS Volume Growth SS Admit Growth Home Health Growth Hospice Growth -2% -1% -2% -2% 0% -2.5% -1.5% -0.5% 0.5% 12,500 12,750 13,000 4Q22 1Q23 2Q23 3Q23 4Q23 ADC
Slide 10: Industry Leading Quality Scores
10 INDUSTRY LEADING QUALITY SCORES Quality of Patient Care (QPC) Patient Satisfaction (PS) • Amedisys maintains a 4-Star average in the Apr 2024 HHC Preview with 95% of our providers (representing 96% of care centers) at 4+ Stars and 65% of our providers (representing 73% of care centers) at 4.5+ St
Slide 11: Hospice Quality: Moving Towards Best-in-Class
11 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers. Exhibit 99.2
Slide 12: Debt and Liquidity Metrics
12 DEBT AND LIQUIDITY METRICS Net leverage ~1.1x 1. Net debt defined as total debt outstanding ($400.8M) less cash ($138.9M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($247.0M). 3. Liquidity defined as the sum of cash balance and available revolvin
Slide 13: Cash Flow Statement Highlights
13 CASH FLOW STATEMENT HIGHLIGHTS (1) Total cash flow from operations for Q4-23 impacted by the timing of the payment of accrued expenses and the collection of accounts receivable. 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.
Slide 14: Income Statement Adjustments
14 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these no
Slide 15: Environmental, Social, Governance (E.S.G.) Considerations
15 Environmental, Social, Governance (E.S.G.) Considerations Exhibit 99.2
Slide 16: Environmental, Social, Governance (E.S.G.) Considerations
16 ENVIRONMENTAL, SOCIAL, GOVERNANCE (E.S.G.) CONSIDERATIONS Sustainable, high-quality, patient focused, home-based care model E n vi ro nmental, Social, Govern an ce Environmental • Amedisys is dedicated to the sustainability of our business and the communities in which we serve • Environmental hea